COMMUNIQUÉS West-GlobeNewswire

PDS Biotech Announces Colorectal Cancer Cohort of Phase 2 Clinical Trial with PDS01ADC Met Criteria for Expansion to Stage 2 Following Positive Stage 1 Results
10/07/2025
Metastatic Colorectal Cancer Cohort in NCI-Led Multi-Cohort Study Demonstrates Promising Response Rate, Triggering Enrollment Expansion Under Simon Two-Stage Design PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS [...]
e-therapeutics De-risks Clinical Path for GalOmic Candidate ETX-312 with Positive Non-clinical Data
10/07/2025
ETX-312 well tolerated at exaggerated dose levels in GLP-compliant toxicology studies GMP manufacturing of clinical trial batch successfully completed On track for CTA submission in Q4 2025 LONDON, July 10, 2025 (GLOBE [...]
TerrAscend to Host Second Quarter 2025 Earnings Conference Call
10/07/2025
TORONTO, July 10, 2025 (GLOBE NEWSWIRE) -- TerrAscend Corp. ("TerrAscend" or the "Company") (TSX: TSND) (OTCQX: TSNDF) , a leading North American cannabis company, today announced that it will host a scheduled [...]
Ligand Partner Pelthos Therapeutics Launches ZELSUVMI™
10/07/2025
JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE American: PTHS) has commercially launched ZELSUVMI™ ( [...]
Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer’s Association International Conference (AAIC®) 2025
10/07/2025
NEWTON, Mass., July 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) [...]
New Bay Area Lyme Foundation Study Reports That Only One-Third of Early Lyme Patients with On-Going Symptoms Followed up with their Healthcare Providers
10/07/2025
The new research, published in Frontiers in Medicine, points to the need for greater follow-up from medical professionals to address potential treatment failures. PORTOLA VALLEY, Calif., July 10, 2025 (GLOBE NEWSWIRE [...]
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
10/07/2025
VANCOUVER, British Columbia, July 10, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next-generation cancer therapies [...]
Epitopea renforce ses capacités de recherche et de développement clinique pour accélérer le passage à la clinique
10/07/2025
CAMBRIDGE, Royaume-Uni et MONTRÉAL, 10 juill. 2025 (GLOBE NEWSWIRE) -- Epitopea, société transatlantique d'immunothérapie anticancéreuse développant des immunothérapies à base d'ARN accessibles et prêtes à l'emploi, a [...]
Epitopea Expands its Clinical Development and Research Capabilities as it Accelerates to the Clinic
10/07/2025
CAMBRIDGE, United Kingdom and MONTREAL, July 10, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, today announced the [...]
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
10/07/2025
REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the [...]
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
10/07/2025
REYKJAVIK, ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of [...]
Osivax Publishes Phase 2a Results Supporting Co-Administration of OVX836 with Seasonal Flu Vaccine in Vaccines Journal
10/07/2025
Co-administration of OVX836 with seasonal inactivated influenza vaccine (Fluarix ® Tetra) was well-tolerated and demonstrated a favorable safety profile Robust complementary immune responses were induced, with no major [...]
Tecan announces CEO transition as part of succession planning
10/07/2025
Ad hoc announcement pursuant to Article 53 of the SIX Exchange Regulation Listing Rules Männedorf, Switzerland, July 10, 2025 – The Tecan Group (SIX Swiss Exchange: TECN) today announced a planned CEO transition, [...]
DXS International plc (AQSE:DXSP): ExpertCare featured in Innovate UK Research Project
10/07/2025
DXS INTERNATIONAL PLC (AQSE: DXSP) ExpertCare featured in Innovate UK Research Project DXS International plc ("DXS" or "the Company"), a leading provider of digital clinical decision support solutions, is thrilled to [...]
Gozellix Receives Permanent HCPCS Code
10/07/2025
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that its next-generation PSMA 1 PET 2 imaging agent, Gozellix® (kit [...]
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
09/07/2025
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with [...]
HNL Lab Medicine Named Empowering Women Award Recipient for 2025
09/07/2025
ALLENTOWN, Pa., July 09, 2025 (GLOBE NEWSWIRE) -- HNL Lab Medicine has been named a recipient of the 2025 Empowering Women Award by Lehigh Valley Business and Central Penn Business Journal, in recognition of its strong [...]
Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update
09/07/2025
Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and Waldenström [...]
Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine
09/07/2025
The previously disclosed and now published RESILIENT data show that once-nightly TNX-102 SL achieved statistically significant improvement in the primary endpoint of reducing fibromyalgia pain versus placebo, and was [...]

Pages